Rosuvastatin (Rsv) is one of statins , which are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase which inhibit endogenous cholesterol synthesis, possess pleiotropic activities, such as anti-inflammatory, anti-oxidative and antifibrotic effects. Dyslipidemia is an important risk factor for acute coronary syndromes and non alcoholic steatohepatitis (NASH).The present study aimed to investigate the effect of Rsv on myocardial necrosis in an experimental model of acute myocardial infarction (AMI).Animals were given standarded chew supplemented with 2% cholesterol for 4 weeks then AMI was induced by isoprenaline injection (150mg/kg s.c), Rsv was given orally (1mg/kg/day) for 4 weeks before induction of AMI & intraperitoneally (i.p) (10 mg/kg) at the onset of AMI. The obtained result from the current work revealed that pretreatreament with Rsv significantly reduced serum lipid , serum CPK-MB ,heart rate ,T-wave voltage and myocardial necrosis and significantly increase serum HDL compared to infracted rats. This study also aimed to investigate whether Rsv ameliorate steatohepatitis using a high-fat and high-cholesterol diet-induced rat model. Animals were administered high fat and high-cholesterol diet via oral gavage for 6 weeks, Rsv was administered for 6 weeks (from the start of the study) and from the 6th week to the 10th week from the start of the study (after induction of NASH) . The obtained results from the current work revealed that pretreatreament and treatment with Rsv produced significant decrease in serum lipid , ALT and AST ,significant increase in serum HDL and improvement of histopathlogical picture compared to hypercholesterolemic with no medication group.Conclusively , Rsv could have a cardioprotective effect against AMI & improved hepatic steatosis |
